KNTE Kinnate Biopharma Inc.

Biotech Analyst Ratings

Latest News

1. 12 May 2022 Kinnate Biopharma Inc. Reports First Quarter 2022 Financial Results and Provides Operational Updates

   Initial monotherapy data from ongoing Phase 1 KN-8701 clinical trial expected in the fourth quarter of 2022

   Announces initiation of the combination portion of Phase 1 KN-8701 clinical trial to evaluate its pan-RAF inhibitor, KIN-2787, with binimetinib in NRAS-mutant melanoma

   First patient dosed in ongoing Phase 1 KN-4802 clinical trial of lead FGFR inhibitor product candidate, KIN-3248; initial data expected in the second half of 2023
           
   Cash runway extended into early 2024, with budget reallocation; Cash, cash equivalents and investments of approximately $302.4 million as of March 31, 2022 (excluding cash from its China joint venture)

   SAN FRANCISCO and SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE…

   View Full Article
2. 18 April 2022 Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of its FGFR Inhibitor Product Candidate, KIN-3248

   SAN FRANCISCO and SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that the first patient has commenced treatment in its Phase 1 KN-4802 (NCT05242822) clinical trial evaluating its lead Fibroblast Growth Factor Receptor (FGFR) product candidate, KIN-3248. KIN-3248 is a next-generation pan-FGFR inhibitor being developed for the treatment of intrahepatic cholangiocarcinoma (ICC) and urothelial carcinoma (UC), as well as other solid tumors.
   

   "With the dosing of the first patient in our Phase 1 trial of KIN-3248, we are excited…

   View Full Article
3. 08 April 2022 Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual Meeting

   SAN FRANCISCO and SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that it will present data from the company's lead RAF kinase inhibitor program, KIN-2787, and its clinico-genomics study investigating the occurrence of BRAF Class II and Class III alterations across solid tumors. The three separate poster presentations will be delivered at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisiana taking place April 8-13, 2022.
   

   "Kinnate continues to make progress with KIN-2787 in our RAF…

   View Full Article
4. 28 March 2022 Kinnate Biopharma Inc. Reports Full Year 2021 Financial Results and Provides Operational Updates

   Initiated Phase 1 clinical trial for KIN-3248 in the first quarter of 2022
   

   Initial monotherapy data from the ongoing KN-8701 Phase 1 trial expected in the third quarter of 2022

   Initiation of the combination portion of KN-8701 to study KIN-2787 with binimetinib in NRAS-mutant melanoma expected in the first half of 2022 with initial data expected by year end 2022

   Cash, cash equivalents and investments of approximately $324.9 million as of December 31, 2021, exclusive of its China joint venture's cash

   SAN FRANCISCO and SAN DIEGO, March 28, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat…

   View Full Article
5. 08 March 2022 Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation at the American Association for Cancer Research Annual Meeting

   SAN FRANCISCO and SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced abstracts highlighting the company's lead RAF kinase inhibitor program, KIN-2787, have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, to be held April 8-13, in New Orleans, Louisiana.
   

   Abstracts accepted for poster presentation include:

   • Occurrence of BRAF class II and III alterations is common across solid tumors and is associated with inferior clinical outcomes in NSCLC and melanoma (PAN…

   View Full Article